Comparison
DSIP vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
62568-57-4
910463-68-2
Molecular weight
848.81 g/mol
4113.6 g/mol
Half-life
0.1 h
165 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glumodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
1
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
5